Biocon Biologics, the biosimilars arm of Biocon Ltd, is set to introduce three new oncology biosimilars, including a biosimilar of pembrolizumab (Keytruda), at the J.P. Morgan Healthcare Conference 2026 in San Francisco.

Alongside the Keytruda biosimilar, the company will also present biosimilars of nivolumab (Opdivo) and trastuzumab/hyaluronidase, further strengthening its oncology pipeline. These additions expand Biocon Biologics’ cancer portfolio and align with its strategy to increase global access to high-cost biologic therapies through more affordable alternatives.

The reference products for these biosimilars rank among the world’s highest-selling oncology drugs and are expected to face patent expiries in key markets over the coming years. Biocon Biologics aims to leverage this opportunity by building a strong late-stage biosimilar pipeline focused on immuno-oncology and targeted cancer therapies.

At JPM 2026, the company is also expected to outline its long-term strategy in biosimilars, including development timelines, manufacturing capabilities and global commercial plans. With these new oncology assets, Biocon Biologics continues to position itself as a leading player in the global biosimilars market, focused on improving patient access while maintaining high standards of quality and compliance.